mAbxience |
mAbxience and Abbott Sign Strategic Agreement to Broaden Access to a Pipeline of Biosimilars in Key Emerging Markets
09/20/2023
mAbxience has announced today an agreement with global healthcare leader Abbott to commercialize several biosimilars focusing on oncology, women’s health, and respiratory diseases in emerging markets. The first molecules are expected to launch in 2025, while others are subject to the completion of clinical development and registration. Abbott will register and commercialize the biosimilars in […]
Boosting biologics and Contract Manufacturing at mAbxience facilities
04/03/2023
CDMO and biosimilars maker mAbxience will install a new ABEC 4,000 L CSR Single use bioreactor at one of its site. mAbxience, a leading international biopharmaceutical company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals is set to continue its ambitious growth plans with the installation of a new […]
HK inno.N licenses in mAbxience’s denosumab biosimilar
01/25/2023
HK inno.N said it has signed an exclusive license agreement with Spain’s mAbxience to market the latter’s Prolia (ingredient: denosumab) biosimilar, a preventive treatment for osteoporosis and cancer-related skeletal complications, in Korea. Under the contract, HK inno.N will exclusively market two types of denosumab biosimilars – 60 mg and 120 mg — from mAbxience, and […]
mAbxience II Biosimilar Forum
10/26/2022
To drive scientific exchange on biopharmaceuticals and high-quality treatment options, more than 180 physicians, pharmacists, and hospital managers from around the world came together in a global conference and over 423 attendees via streaming. On October 21, mAbxience, a leading international biopharmaceutical company of which Fresenius Kabi acquired a majority stake, has celebrated its 2nd […]
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
08/01/2022
A further milestone for Fresenius Kabi’s Vision 2026 growth strategy as the company invests on the core growth vector “Broaden in Biopharma” The combination of both companies positions Fresenius Kabi for accelerated medium- and long-term growth building on a highly complementary product offering in one of the fastest-growing areas of healthcare Enables entry into high-growth […]
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience
04/19/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin®. The product will be marketed under the proprietary name ALYMSYS® and represents the third bevacizumab biosimilar approved in the U.S. ALYMSYS® was developed […]